Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Completed · Phase 2

Conditions studied: Hodgkin Disease

In brief

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.

Key facts

Study ID

NCT02181738

Run by

Bristol-Myers Squibb

People needed

294

Starts

2014-08-12

Expected to finish

2022-12-27

Last updated by the study team

2023-11-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Must have received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B \& C - enrollment closed)
• Participants may be Brentuximab vedotin- naïve, or may have had prior Brentuximab vedotin treatment (cohort A, B \& C - enrollment closed)
• Newly diagnosed and previously untreated classical Hodgkin Lymphoma (cohort D)

You may not qualify if…

• Known central nervous system lymphoma
• Participants with nodular lymphocyte-predominant Hodgkin Lymphoma
• Prior allogeneic stem cell transplantation (SCT)
• Chest radiation ≤ 24 weeks prior to first dose
• Carmustine ≥ 600 mg/m² received as part of the pre-transplant conditioning regimen

Where it is running

• Local Institution - 0030 — Los Angeles, California, United States
• Local Institution - 0009 — Los Angeles, California, United States
• Local Institution - 0001 — Atlanta, Georgia, United States
• Local Institution - 0002 — Boston, Massachusetts, United States
• Local Institution - 0025 — Boston, Massachusetts, United States
• Local Institution - 0041 — Boston, Massachusetts, United States
• Local Institution - 0008 — Detroit, Michigan, United States
• Local Institution - 0003 — Rochester, Minnesota, United States
• Local Institution - 0047 — Hackensack, New Jersey, United States
• Local Institution - 0040 — Basking Ridge, New York, United States
• Local Institution - 0005 — New York, New York, United States
• Local Institution - 0006 — Allentown, Pennsylvania, United States
• Local Institution - 0004 — Nashville, Tennessee, United States
• Local Institution - 0007 — Houston, Texas, United States
• Local Institution - 0032 — Innsbruck, Austria
• Local Institution - 0031 — Vienna, Austria
• Local Institution - 0014 — B-leuven, Belgium
• Local Institution - 0015 — Ghent, Belgium
• Local Institution - 0046 — Vancouver, British Columbia, Canada
• Local Institution - 0042 — Toronto, Ontario, Canada
• Local Institution - 0044 — Prague, Czechia
• Local Institution - 0037 — Berlin, Germany
• Local Institution - 0033 — Cologne, Germany
• Local Institution - 0036 — Hamburg, Germany
• Local Institution - 0034 — Ulm, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.